Tykerb: Phase III data

Researchers at the German Breast Group and colleagues reported data from the open-label, German Phase III GeparQuinto trial in 615 evaluable previously untreated HER2-positive advanced breast cancer patients showing that a significantly greater proportion of patients receiving Herceptin trastuzumab plus chemotherapy (epirubicin plus cyclophosphamide and docetaxel) achieved a pCR, the primary endpoint, vs. Tykerb lapatinib plus chemotherapy (30.3% vs. 22.7%, p=0.04). Data were published in The Lancet Oncology. ...